original ) (raw )Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia
Lian Mao
CNS spectrums, 2016
View PDFchevron_right
Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia
Lian Mao
The Journal of Clinical Psychiatry, 2015
View PDFchevron_right
A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia
Lian Mao
Schizophrenia Research, 2016
View PDFchevron_right
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia
Panna Sanga
International Journal of Neuropsychopharmacology, 2021
View PDFchevron_right
Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia
Cherubin, Pierre [JACFR] , Andreas Schreiner
Schizophrenia Research, 2015
View PDFchevron_right
Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
Anthony Harris
Neuropsychiatric disease and treatment, 2015
View PDFchevron_right
Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
Boran Uglešić
Neuropsychiatric Disease and Treatment
View PDFchevron_right
Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia
Andreas Conca
Expert Opinion on Pharmacotherapy, 2016
View PDFchevron_right
Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration
Euitae Kim
The Journal of Clinical Psychiatry, 2021
View PDFchevron_right
Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review
Clemente Garcia-rizo , Rafael Penadés , Alexandre G González-Rodríguez
Patient Preference and Adherence, 2015
View PDFchevron_right
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Adam Savitz
Neuropsychiatric Disease and Treatment, 2019
View PDFchevron_right
Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review
Miquel Bioque , Alexandre G González-Rodríguez , Rafael Penadés
Patient preference and adherence, 2015
View PDFchevron_right
A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia
Pilar Lim
Neuropsychopharmacology, 2010
View PDFchevron_right
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
Adam Savitz
The International Journal of Neuropsychopharmacology, 2016
View PDFchevron_right
Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients
Erik Muser
Journal of Comparative Effectiveness Research, 2015
View PDFchevron_right
Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
Helio Elkis
Neuropsychiatric Disease and Treatment
View PDFchevron_right
Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response …
Paulien Ravenstijn
International clinical …, 2010
View PDFchevron_right
Design and Rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) Study: A Novel Comparative Trial of Once-Monthly Paliperidone Palmitate Versus Daily Oral Antipsychotic Treatment for Delaying Time to Treatment #01#
Joe Hulihan
The Journal of Clinical Psychiatry, 2014
View PDFchevron_right
Effectiveness of Paliperidone Palmitate vs. Haloperidol Decanoate for Maintenance Treatment of Schizophrenia: A Randomized Clinical Trial NIH Public Access Author Manuscript
Pablo Menendez
View PDFchevron_right
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study
Robert Litman
The International Journal of Neuropsychopharmacology, 2009
View PDFchevron_right
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study
Pilar Lim
Schizophrenia Research, 2010
View PDFchevron_right
A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia
Pilar Lim
Journal of Psychopharmacology, 2011
View PDFchevron_right
Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study
Cenk Varlik
International Clinical Psychopharmacology, 2010
View PDFchevron_right
Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics
Cherubin, Pierre [JACFR] , Paul Bergmans , Behcet Coşar
View PDFchevron_right
A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents
Ludger Hargarter , Andreas Schreiner , Yasin Bez
Clinical therapeutics, 2014
View PDFchevron_right
Efficacy of paliperidone palmitate in the treatment of schizophrenia and its effect on psychosocial and occupational functioning in patients: 2 Case studies
Sahar Arshed
2016
View PDFchevron_right
Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics
Ludger Hargarter , Sofia Keim , Paul Bergmans
Progress in neuro-psychopharmacology & biological psychiatry, 2015
View PDFchevron_right